X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (381) 381
Patent (54) 54
Publication (7) 7
Conference Proceeding (5) 5
Book Chapter (1) 1
Book Review (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (139) 139
index medicus (137) 137
female (108) 108
male (107) 107
aged (101) 101
middle aged (93) 93
oncology (90) 90
adult (63) 63
cancer (61) 61
chemotherapy (52) 52
physics (52) 52
aged, 80 and over (46) 46
surgery (45) 45
testing (39) 39
measuring (38) 38
analysis (36) 36
treatment outcome (36) 36
care and treatment (35) 35
neoplasm staging (33) 33
gyroscopic instruments (31) 31
measuring distances, levels or bearings (31) 31
navigation (31) 31
photogrammetry or videogrammetry (31) 31
signalling (31) 31
surveying (31) 31
traffic control systems (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
prognosis (30) 30
clinical trials (29) 29
japan (29) 29
survival (29) 29
medicine & public health (27) 27
patients (27) 27
colorectal cancer (26) 26
research (26) 26
retrospective studies (24) 24
disease-free survival (21) 21
cisplatin (20) 20
lung neoplasms - drug therapy (20) 20
lung neoplasms - pathology (20) 20
surgical oncology (19) 19
carcinoma, non-small-cell lung - drug therapy (18) 18
metastasis (18) 18
prospective studies (18) 18
follow-up studies (17) 17
models (17) 17
survival rate (17) 17
advertising (16) 16
appliances for teaching, or communicating with, the blind,deaf or mute (16) 16
carcinoma, non-small-cell lung - pathology (16) 16
cryptography (16) 16
diagrams (16) 16
display (16) 16
education (16) 16
educational or demonstration appliances (16) 16
globes (16) 16
kaplan-meier estimate (16) 16
maps (16) 16
planetaria (16) 16
seals (16) 16
trial (16) 16
animals (15) 15
diagnosis (15) 15
fluorouracil (15) 15
cancer therapies (14) 14
health aspects (14) 14
information storage (14) 14
information storage based on relative movement between recordcarrier and transducer (14) 14
lung cancer (14) 14
survival analysis (14) 14
abridged index medicus (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
bevacizumab (13) 13
gastroenterology & hepatology (13) 13
metastases (13) 13
oncology, experimental (13) 13
studies (13) 13
therapy (13) 13
usage (13) 13
carcinoma, non-small-cell lung - mortality (12) 12
drug combinations (12) 12
expression (12) 12
gastric cancer (12) 12
lung cancer, non-small cell (12) 12
lung neoplasms - mortality (12) 12
mortality (12) 12
multivariate analysis (12) 12
young adult (12) 12
cancer research (11) 11
colorectal carcinoma (11) 11
colorectal neoplasms - drug therapy (11) 11
docetaxel (11) 11
leucovorin (11) 11
medical research (11) 11
radiotherapy (11) 11
respiratory system (11) 11
risk factors (11) 11
stomach cancer (11) 11
calculating (10) 10
carcinoma (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2181 - 2190
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1630 - 1638
Journal Article
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), ISSN 1345-2843, 2018, Volume 79, Issue 7, pp. 1566 - 1568
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 6/2016, Volume 21, Issue 3, pp. 523 - 530
Journal Article
Nature Methods, ISSN 1548-7091, 05/2015, Volume 12, Issue 6, pp. 515 - 518
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 3, pp. 626 - 637.e7
Journal Article